Aug. 2 at 11:44 PM
$RANI [Again] It is important to highlight that the Rani-Pill offers a possible pill solution to ALL biologics globally over injection. That equates to a Total Addressable Market of nearly
$56BILS, while the Company is presently valued at
$105MILS. The Company is proceeding with its own product pipeline (separate and concurrent) across GLP1/2 (RT-114),
$100BILS, Type-II Diabetes
$10-20BILS, Osteoporosis RT-102 , Psoriasis
$20BILS and others. The PT here near/intermediate term is approximately
$3-8; however, the broad application of RaniPill across multiple biologics (as the partnerships with Chugai and PegBio suggest) could theoretically take the PT here long-term over
$15-25 (IMO). It is presently trading at/around
$0.70.
